Bioengineered AAV9 and Optimised Microdystrophin Vectors Augment Phenotypic Rescue in a Murine Model of Duchenne Muscular Dystrophy
Journal of Cellular and Molecular Medicine · 2026
DOI: 10.1111/jcmm.71078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2026. Verfasst von Mohankumar B Senthilkumar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences and Bioengineering and Mehta Family Center for Engineering in Medicine and Gangwal School of Medical Sciences and T…. Hauptthemen laut MEDLINE: Dependovirus, Muscular Dystrophy, Duchenne, Dystrophin, Genetic Vectors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Wellcome Trust DBT India Alliance, Indian Institute of Technology Kanpur, Wellcome Trust DBT India Alliance.
Abstract (Originalsprache)
Duchenne muscular dystrophy (DMD) is a severe neuromuscular disorder without an effective cure. Adeno‐associated virus (AAV) based gene therapy has improved dystrophin function, with sub‐optimal clinical outcomes. We reasoned that a combination of rational engineering of AAV9 capsids modified at the post‐translational modification sites, optimal promoter selection, and codon‐optimisation of the microdystrophin (μDys) can enhance the AAV9 vector functionality. Our initial promoter screening demonstrated improved dystrophin expression in muscle fibres with a ubiquitous CAG promoter (1.61‐fold in CAG vs. MHCK7, p < 0.0001) in mdx mice. We then evaluated two engineered AAV9 capsids (N57Q, K51Q) containing CAG‐μDys intramuscularly in vivo, which demonstrated a significant improvement in grip strength 18 weeks after gene therapy. Subsequent evaluation of a codon‐optimised microdystrophin transgene under the control of the optimal CAG promoter and capsid (AAV9K51Q) by intramuscular administration revealed enhanced muscle grip strength and dystrophin‐glycoprotein complex restoration up to 4 months after gene therapy. Based on the improved performance of AAV9K51Q vectors during intramuscular gene transfer, we performed a systemic administration of these vectors alone, and a comparison with the control group revealed a significantly increased muscle contraction force by 1.6–1.7 fold and a 30%–60% dystrophin restoration in skeletal and cardiac muscles, up to 14 months after gene therapy. Collectively, our study underscores the therapeutic potential of engineered AAV9 vectors for potential clinical application in patients with DMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences and Bioengineering and Mehta Family Center for Engineering in Medicine and Gangwal School of Medical Sciences and Technology, Indian Institute of Technology, Kanpur, Uttar Pradesh, Indi…
- School of Biomedical Engineering, IIT (BHU), Varanasi, Uttar Pradesh, India.
- Autonomous State Medical College, Kanpur, Uttar Pradesh, India.
- Institute of Medical Genetics and Genomics, Sir Gangaram Hospital, New Delhi, India.
- Department of Neurology, University of Washington School of Medicine, Seattle, Washington, USA.
- Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
ORCID-Profile: Sudip Mukherjee, Sameer Bhatia
Förderung
- The Wellcome Trust DBT India Alliance
- Indian Institute of Technology Kanpur
- Wellcome Trust DBT India Alliance
Zitieren
APA
Senthilkumar, M. B., Sharma, S., Srinivasan, N., Varghese, A., Sarangi, P., Singh, V., Kumar, N., Yenurkar, D., Mukherjee, S., Amit, S., Bhatia, S., Misra, S. K., Puri, R. D., Chamberlain, J., & Jayandharan, G. R. (2026). Bioengineered AAV9 and Optimised Microdystrophin Vectors Augment Phenotypic Rescue in a Murine Model of Duchenne Muscular Dystrophy. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.71078
Vancouver
Senthilkumar MB, Sharma S, Srinivasan N, Varghese A, Sarangi P, Singh V, et al. Bioengineered AAV9 and Optimised Microdystrophin Vectors Augment Phenotypic Rescue in a Murine Model of Duchenne Muscular Dystrophy. Journal of Cellular and Molecular Medicine. 2026. doi:10.1111/jcmm.71078
BibTeX
@article{Senthilkumar2026,
author = {Senthilkumar, Mohankumar B and Sharma, Sanya and Srinivasan, Navaneeth and Varghese, Anila and Sarangi, Pratiksha and Singh, Vijayata and Kumar, Narendra and Yenurkar, Devyani and Mukherjee, Sudip and Amit, Sonal and Bhatia, Sameer and Misra, Santosh K and Puri, Ratna Dua and Chamberlain, Jeffrey and Jayandharan, Giridhara R},
title = {Bioengineered AAV9 and Optimised Microdystrophin Vectors Augment Phenotypic Rescue in a Murine Model of Duchenne Muscular Dystrophy},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
doi = {10.1111/jcmm.71078}
}
EUVIMED